Though down nearly 6% in January, the BioWorld Drug Developers Index (BDDI) rebounded in February, finishing the month with a 4.41% increase and outperforming both the Nasdaq Biotechnology Index (NBI; up 1.33%) and the Dow Jones Industrial Average (DJIA; up 3.47%). In 2023, BDDI concluded the year down 11.35%, trailing behind the NBI and DJIA.
Getting a drug successfully through clinical development in amyotrophic lateral sclerosis (ALS) continues to be an elusive task, with Denali Therapeutics Inc. and partner Sanofi SA reporting the latest failure in the progressive neurodegenerative disease.
Denali Therapeutics Inc. has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of Alzheimer's disease, atherosclerosis, asthma, nonalcoholic fatty liver disease (NAFLD), multiple sclerosis (MS), experimental autoimmune encephalitis, type 1 diabetes and rheumatoid arthritis, among others.
Denali Therapeutics Inc. has patented new NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of glaucoma, spinal cord Injury, leukoencephalopathy, mitochondrial disease, multiple sclerosis, Niemann-Pick disease, spinal muscular atrophy and stroke, among others.
For the second time in a week, measures of serum neurofilament light chain (NfL) took center stage, this time as Denali Therapeutics Inc. unveiled interim data from the open-label, single-arm phase I/II study testing DNL-310 in children with mucopolysaccharidosis II (MPS II), also known as Hunter syndrome.
Mucopolysaccharidosis type IIIA (MPS IIIA) is a genetic disorder where mutations in SGSH lead to the accumulation of heparan sulfate (HS) and lysosomal dysfunction that translate into developmental delay and cognition decline in humans. To date, there is no cure for MPS IIIA and that is why finding new strategies is an urgent need.
Denali Therapeutics Inc.’s extensive update on clinical programs in central nervous system diseases at the start of this year included plans for lead asset DNL-310 in mucopolysaccharidosis II (MPS II), also known as Hunter syndrome – a space where other notable players include such names as Regenxbio Inc. and Takeda Pharmaceutical Co. Ltd.
Denali Therapeutics Inc.’s extensive update on clinical programs in central nervous system diseases at the start of this year included plans for lead asset DNL-310 in mucopolysaccharidosis II (MPS II), also known as Hunter syndrome – a space where other notable players include such names as Regenxbio Inc. and Takeda Pharmaceutical Co. Ltd.
Denali Therapeutics Inc. has disclosed NLRP3 inflammasome inhibitors reported to be useful for the treatment of stroke, gout, multiple sclerosis, Alzheimer's disease, hypertension, silicosis, graft-versus-host disease and nonalcoholic steatohepatitis (NASH).
Secarna Pharmaceuticals GmbH & Co. KG and Denali Therapeutics Inc. have expanded a central nervous system research partnership as the gene silencing field heats up.